HEALEY Trial Fully Enrolled for 2 Regimens; Data Expected by Mid-2022

HEALEY Trial Fully Enrolled for 2 Regimens; Data Expected by Mid-2022

312086

HEALEY Trial Fully Enrolled for 2 Regimens; Data Expected by Mid-2022

The HEALEY ALS platform trial, the first study to test several therapy candidates for amyotrophic lateral sclerosis (ALS) simultaneously, has completed enrollment for at least two of its first three regimens. These include Clene Nanomedicine’s CNM-Au8 (NCT04414345) and Biohaven Pharmaceuticals’ verdiperstat (NCT04436510). The recruitment status for the other initial arm of the trial, UCB’s zilucoplan (NCT04436497), remains unclear, but all three regimens reached 50% of their target enrollment in March. Pridopidine, being developed by Prilenia…

You must be logged in to read/download the full post.